awmsg logo



lipegfilgrastim (Lonquex®)


Reference No. 1297

Publication date:
14/08/2014


Last review date:
29/09/2017

Appraisal information

lipegfilgrastim (Lonquex®) 6 mg solution for injection


Company: TEVA UK Ltd
BNF category: Nutrition and blood
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1714
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lipegfilgrastim (Lonquex®) is recommended as an option for restricted use within NHS Wales for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Lipegfilgrastim (Lonquex®) should be restricted for use where a long-acting granulocyte colony-stimulating factor (G-CSF) is appropriate. Lipegfilgrastim (Lonquex®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download